STOCK TITAN

Adaptive Biotechnologies (ADPT) CPO sells 39,741 shares after option exercises

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp Chief People Officer Francis Lo reported a series of stock option exercises and a same-day share sale in Common Stock. On June 4, 2026, Lo exercised options covering 19,521 shares at strike prices ranging from $3.99 to $12.14 per share, receiving an equivalent number of common shares.

On the same date, Lo completed an open-market sale of 39,741 Common Stock shares at an average price of $17.49 per share. Following these transactions, Lo holds 250,934 Common Stock shares directly and 2,500 shares indirectly through a spouse. The filing notes that these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2025, indicating they were scheduled in advance rather than timed discretionarily.

Positive

  • None.

Negative

  • None.
Insider LO FRANCIS
Role Chief People Officer
Sold 39,741 shs ($695K)
Type Security Shares Price Value
Exercise Stock Option (right to buy) 5,792 $0.00 --
Exercise Stock Option (right to buy) 2,009 $0.00 --
Exercise Stock Option (right to buy) 2,344 $0.00 --
Exercise Stock Option (right to buy) 9,376 $0.00 --
Exercise Common Stock 5,792 $12.14 $70K
Exercise Common Stock 2,009 $8.46 $17K
Exercise Common Stock 2,344 $3.99 $9K
Exercise Common Stock 9,376 $8.12 $76K
Sale Common Stock 39,741 $17.49 $695K
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (right to buy) — 171,823 shares (Direct, null); Common Stock — 276,946 shares (Direct, null); Common Stock — 2,500 shares (Indirect, By You Jin Lee (spouse))
Footnotes (1)
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. The option is fully vested and exercisable. The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Shares sold 39,741 shares Common Stock open-market sale on June 4, 2026 at $17.49
Sale price $17.49 per share Average price for 39,741 Common Stock shares sold
Options exercised 19,521 shares Total Common Stock from option exercises on June 4, 2026
Post-transaction direct holdings 250,934 shares Common Stock directly held by Francis Lo after transactions
Indirect holdings via spouse 2,500 shares Common Stock held by spouse, reported as indirect ownership
Lowest option strike $3.99 per share One of the stock option exercise prices
Highest option strike $12.14 per share One of the stock option exercise prices
Rule 10b5-1 trading plan regulatory
"transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Stock Option (right to buy) financial
"security_title": "Stock Option (right to buy)""
Chief People Officer financial
"officer_title": "Chief People Officer""
A chief people officer is a senior executive responsible for overseeing a company's workforce and human resources strategies. They focus on attracting, developing, and retaining employees, ensuring a positive workplace culture, and aligning staff efforts with the company's goals. For investors, this role matters because strong leadership in managing people can drive productivity, innovation, and overall company performance.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LO FRANCIS

(Last)(First)(Middle)
C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION
1165 EASTLAKE AVENUE EAST

(Street)
SEATTLE WASHINGTON 98109

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief People Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/04/2026M(1)5,792A$12.14276,946D
Common Stock06/04/2026M(1)2,009A$8.46278,955D
Common Stock06/04/2026M(1)2,344A$3.99281,299D
Common Stock06/04/2026M(1)9,376A$8.12290,675D
Common Stock06/04/2026S(1)39,741D$17.49250,934D
Common Stock2,500IBy You Jin Lee (spouse)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$12.1406/04/2026M(1)5,792 (2)03/04/2032Common Stock5,792$0171,823D
Stock Option (right to buy)$8.4606/04/2026M(1)2,009 (3)03/06/2033Common Stock2,009$085,065D
Stock Option (right to buy)$3.9906/04/2026M(1)2,344 (4)03/04/2034Common Stock2,344$085,953D
Stock Option (right to buy)$8.1206/04/2026M(1)9,376 (5)03/04/2035Common Stock9,376$0140,648D
Explanation of Responses:
1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
2. The option is fully vested and exercisable.
3. The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
4. The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
5. The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
/s/ Francis Lo by Kyle Piskel, Attorney-in-Fact06/04/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did ADPT Chief People Officer Francis Lo report?

Francis Lo reported option exercises and an open-market sale of Adaptive Biotechnologies Corp Common Stock. He exercised options for 19,521 shares, then sold 39,741 shares at $17.49 per share, with all activity occurring on June 4, 2026 under a trading plan.

How many Adaptive Biotechnologies (ADPT) shares did Francis Lo sell?

Francis Lo sold 39,741 shares of Adaptive Biotechnologies Corp Common Stock. The transaction was an open-market sale at an average price of $17.49 per share on June 4, 2026, as disclosed in the Form 4 filing.

How many ADPT shares does Francis Lo hold after these transactions?

After the reported transactions, Francis Lo holds 250,934 Adaptive Biotechnologies Corp Common Stock shares directly. In addition, 2,500 shares are held indirectly through his spouse, providing a combined view of his direct and spousal-related ownership following the June 2026 activity.

Were Francis Lo’s Adaptive Biotechnologies trades under a Rule 10b5-1 plan?

Yes. The Form 4 states that the transactions were effected under a Rule 10b5-1 trading plan adopted on September 15, 2025. Such plans pre-schedule trades, indicating the timing of these June 2026 transactions was established in advance rather than decided opportunistically.

What stock options did Francis Lo exercise in this ADPT Form 4?

Francis Lo exercised options covering 19,521 shares of Adaptive Biotechnologies Corp Common Stock. The exercised options had strike prices including $3.99, $8.12, $8.46, and $12.14 per share, converting these derivative positions into common shares on June 4, 2026.